Analytica chimica acta · 2025
Microwave plasma treated Sn/SnO2 and graphite nanocomposites to synergistically promote electrochemical sensing performance toward dopamine and uric acid.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hartanto Danang Tri, Tung Jui-Yu, Aziz Galang Dhaifullah Abdul, Kusumastuti Yuni, Shirosaki Yuki, Wang Meng-Jiy
Аннотация
BACKGROUND: The investigation of biomolecules is essential due to abnormalities in biological metabolism in the human body. Dopamine (DA) and uric acid (UA) are important chemicals that coexist in biological systems and play crucial roles in various physiological processes related to human metabolism. This study explores the application of carbon and SnO2 nanoparticles for DA and UA sensing, focusing on the preparation of Sn/SnO2 nanocomposites through electrospinning and plasma treatment. The research aims to measure these concentrations quickly and accurately, offering advantages such as low manufacturing costs and environmental friendliness.
RESULT: This study presents a novel Sn/SnO2 nanocomposites as an electrocatalyst for the detection of dopamine (DA) and uric acid (UA) levels. Sn/SnO2 nanocomposites were effectively obtained by argon microwave plasma (ArMP) treatment, a dry and green process, on electrospun fibers containing SnCl2 within 120 s. The resultant Sn/SnO2 nanocomposites provide excellent electrochemical catalytic effects to quantify the levels of DA and uric acid UA, which are the two important physiological molecules. To further incorporate graphite into ArMP-Sn/SnO2 can modulate precise differentiation of the oxidation peaks of DA, UA, and ascorbic acid (AA), solving the problems of overlapped oxidation potential among biomolecules. The as-established nanocomposites revealed excellent applicability to be incorporated onto difference substrates including gold electrode (AuE), screen-printed carbon electrodes (SPCE), and flexible carbon electrodes (FCE), providing great potential for building point-of-care sensing platform.
SIGNIFICANCE: The 1%g-120s-ArMP-Sn/SnO2@AuE resulting the highest sensing performance for DA and UA, which the linear detection range was 0.1-400 μM and 0.1-900 μM, with sensitivity of 473.72 and 169.21 μA/mM.cm2, and LOD 0.003 and 0.010 μM, respectively. Additionally, in the areal human fluid matrix the sensor obtains a recovery rate between 95.28 % and 102.72 % with a high selectivity (less than 5 %) upon the presence of common interferences in body fluid.
RESULT: This study presents a novel Sn/SnO2 nanocomposites as an electrocatalyst for the detection of dopamine (DA) and uric acid (UA) levels. Sn/SnO2 nanocomposites were effectively obtained by argon microwave plasma (ArMP) treatment, a dry and green process, on electrospun fibers containing SnCl2 within 120 s. The resultant Sn/SnO2 nanocomposites provide excellent electrochemical catalytic effects to quantify the levels of DA and uric acid UA, which are the two important physiological molecules. To further incorporate graphite into ArMP-Sn/SnO2 can modulate precise differentiation of the oxidation peaks of DA, UA, and ascorbic acid (AA), solving the problems of overlapped oxidation potential among biomolecules. The as-established nanocomposites revealed excellent applicability to be incorporated onto difference substrates including gold electrode (AuE), screen-printed carbon electrodes (SPCE), and flexible carbon electrodes (FCE), providing great potential for building point-of-care sensing platform.
SIGNIFICANCE: The 1%g-120s-ArMP-Sn/SnO2@AuE resulting the highest sensing performance for DA and UA, which the linear detection range was 0.1-400 μM and 0.1-900 μM, with sensitivity of 473.72 and 169.21 μA/mM.cm2, and LOD 0.003 and 0.010 μM, respectively. Additionally, in the areal human fluid matrix the sensor obtains a recovery rate between 95.28 % and 102.72 % with a high selectivity (less than 5 %) upon the presence of common interferences in body fluid.